SAN2219
Strong seizure control without adverse effect
SAN2219: unique subtype selective activation of GABAA receptors for dampening of excessive neuronal activation: a novel method for seizure control.
How SAN2219 works
GABA is a neurotransmitter that mediate inhibitory signaling between nerve cells in the brain. Most forms of epilepsy are caused by an over-excitability in specific neural circuits and dampening of the over-excitability is a well-documented mechanism of most anti-epileptic drugs. Enhancing the effects of GABA through positive modulation of the GABAA receptor is among the most effective treatment principles for control of seizure activity. However, a general reduction of neuronal excitability, by for instance the group of non-selective GABAA modulators named the Benzodiazepines, is often accompanied by adverse effects in the form of sedation, cognitive impairment, motoric instability and tolerance development. These adverse effects are known to be caused primarily by activity of the GABAA α1 containing receptors.
SAN2219 has been specifically designed to selectively modulate GABAA α2, α3 and α5-containing receptors, resulting in a robust inhibition of seizure activity without the well-known GABAA α1 mediated side effects of benzodiazepines. The preclinical data supports that SAN2219 may be used for acute and chronic treatment of prevalent epilepsy forms as well as specific epilepsy syndromes.
SAN2219 STATUS
Saniona’s novel antiepileptic candidate has been selected for preclinical development